Form 4 holding
Chief Executive Officer, Director
MoonLake Immunotherapeutics
- Security class
- Class A ordinary shares, par value $0.0001 per share
- Shares / value
- 2,774,893
- Estimated value
- $55,553,357
- Report date
- 10 Jul 2026
- Price
- $20.02
- Ownership
- Direct